Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
Sashiananthan GaneshananthanNisar ShahParin ShahHossam ElsayedJulie PhillipsAnn ParkesAngharad MorganZaheer YousefPublished in: Open heart (2020)
This study provides real-world clinical practice data demonstrating incremental improvements in functional and echocardiographic outcomes in optimally treated patients with HFrEF switched to sacubitril/valsartan. The data provide evidence beyond that observed in clinical trial settings of the potential benefits of sacubitril/valsartan when used as part of a multidisciplinary heart failure programme.
Keyphrases
- ejection fraction
- heart failure
- clinical trial
- clinical practice
- electronic health record
- left ventricular
- big data
- study protocol
- pulmonary hypertension
- mitral valve
- atrial fibrillation
- type diabetes
- left atrial
- phase ii
- adipose tissue
- combination therapy
- risk assessment
- cardiac resynchronization therapy
- metabolic syndrome
- double blind
- machine learning
- climate change
- newly diagnosed